<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00827814</url>
  </required_header>
  <id_info>
    <org_study_id>2006-06-022</org_study_id>
    <nct_id>NCT00827814</nct_id>
  </id_info>
  <brief_title>Effect of Dutasteride on Bladder Wall Hypertrophy in Patients With Benign Prostatic Obstruction</brief_title>
  <official_title>Effect of Dutasteride on Bladder Wall Hypertrophy in Patients With Benign Prostatic Obstruction: A 24-Week Open-Label, Single-Arm Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Increased bladder mass occurs as a consequence of bladder outlet obstruction in animals and&#xD;
      patients, and relief of bladder outlet obstruction reverses an increased bladder mass.&#xD;
      Whether increased bladder mass is not only a consequence of bladder outlet obstruction but&#xD;
      also a relevant risk factor for the progression of lower urinary tract symptoms associated&#xD;
      with benign prostate hyperplasia cannot be decided due to a lack of appropriate data, most&#xD;
      likely because bladder wall thickness is not routinely measured in clinical studies and/or&#xD;
      routine clinical practice. Despite this lack of data, many urologists feel that increased&#xD;
      bladder mass should be prevented or decreased to reduce the occurrence of serious&#xD;
      complications.&#xD;
&#xD;
      The possibility of using bladder wall thickness data as criteria for benign prostate&#xD;
      hyperplasia intervention and as outcome criteria for benign prostate hyperplasia treatment&#xD;
      has been proposed. Detrusor hypertrophy associated with bladder outlet obstruction can be&#xD;
      imaged on suprapubic ultrasound, and bladder mass can be quantified from the evaluation of&#xD;
      bladder wall thickness and bladder volume. Bladder wall hypertrophy has been found to be&#xD;
      correlated with detrusor function.&#xD;
&#xD;
      Independent studies have shown that surgical treatment of benign prostatic obstruction&#xD;
      results in a significant decrease of bladder mass. Preliminary data suggest the possibility&#xD;
      that medical treatment with alpha-adrenergic antagonists might also produce a reduction of&#xD;
      bladder wall hypertrophy.&#xD;
&#xD;
      The investigators assume that the prevention of benign prostate hyperplasia progression by&#xD;
      alpha-adrenergic antagonists and 5 alpha reductase inhibitors may be result of bladder&#xD;
      function protection. To our knowledge there have been no studies that evaluated the effects&#xD;
      of a 5 alpha reductase inhibitors on bladder function. Therefore, the investigators plan to&#xD;
      conduct a prospective trial evaluating the effects of 5 alpha reductase inhibitors on bladder&#xD;
      function by the evaluation of bladder wall thickness and lower urinary tract symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1 Objective&#xD;
&#xD;
      1.1 Primary Objective: To explore the efficacy of Dutasteride in reducing bladder wall&#xD;
      hypertrophy from baseline to 6 months of treatment in male patients with benign prostatic&#xD;
      obstruction.&#xD;
&#xD;
      1.2 Secondary Objective:&#xD;
&#xD;
        1. To explore the efficacy of Dutasteride in reducing the LUTS symptoms, number of&#xD;
           micturitions, and number of urgency episodes from baseline to 6 months of treatment&#xD;
&#xD;
        2. To explore the efficacy of Dutasteride on the urodynamic parameters from baseline to 6&#xD;
           months of treatment.&#xD;
&#xD;
        3. To explore the efficacy of Dutasteride on the tolerability, safety, patient perception&#xD;
           and quality of life from baseline to 6 months of treatment.&#xD;
&#xD;
      2 Endpoints&#xD;
&#xD;
      2.1 Primary Endpoint: Percent (numeric) changes in ultrasound-estimated bladder weight (UEBW)&#xD;
      from baseline to 6 months of treatment&#xD;
&#xD;
      2.2 Secondary Endpoint:&#xD;
&#xD;
      Urodynamic parameters: From baseline to 6 months of treatment&#xD;
&#xD;
      • Percentage and numeric changes of the&#xD;
&#xD;
        -  Maximum flow rate (mL/s)&#xD;
&#xD;
        -  Average flow rate (mL/s)&#xD;
&#xD;
        -  Post-void residual urine volume (mL)&#xD;
&#xD;
      Micturition diary efficacy parameters: From baseline to 6 months of treatment&#xD;
&#xD;
        -  Percentage and numeric changes in micturition frequency/24 hours&#xD;
&#xD;
        -  Percentage and numeric changes in mean volume voided per micturition&#xD;
&#xD;
        -  Percentage and numeric changes in mean number and severity of urgency per micturition&#xD;
&#xD;
      Prostate volume parameters:&#xD;
&#xD;
      • Change in prostate volume by TRUS from baseline to after 6 months of treatment.&#xD;
&#xD;
      • Change in serum PSA from baseline to after 6 months of treatment.&#xD;
&#xD;
      Quality of life parameters:&#xD;
&#xD;
      • Change in Bother Score of IPSS score from baseline to 6 months of treatment&#xD;
&#xD;
      LUTS Symptom parameters:&#xD;
&#xD;
      • Change in IPSS score from baseline to 6 months of treatment&#xD;
&#xD;
      - total score: sum of all 7 questions&#xD;
&#xD;
        -  storage score: sum of questions 2, 4 and 7&#xD;
&#xD;
        -  voiding score: sum of questions 1, 3, 5 and 6&#xD;
&#xD;
      LUTS outcome score (LOS)&#xD;
&#xD;
      • Change in LOS from baseline to 6 months of treatment&#xD;
&#xD;
      Patient perceptions:&#xD;
&#xD;
        -  Patient perception of treatment benefit after 3 and 6 months of treatment&#xD;
&#xD;
        -  Change in patient perception of urgency from baseline to 3 and 6 month of treatment&#xD;
&#xD;
      Safety parameters:&#xD;
&#xD;
      • Incidence and severity of adverse events&#xD;
&#xD;
      • Incidence and reason of withdrawals&#xD;
&#xD;
      3. STUDY DESIGN AND METHODS&#xD;
&#xD;
      Study Design: This is a 6-month prospective Phase IV study to explore the effect on the&#xD;
      bladder function of Dutasteride in male patients with benign prostatic obstruction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent (numeric) changes in ultrasound-estimated bladder weight (UEBW)</measure>
    <time_frame>Baseline and 6 months of dutasteride treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urodynamic parameters</measure>
    <time_frame>Baseline and 3 and/or 6 months of dutasteride treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Micturition diary efficacy parameters</measure>
    <time_frame>Baseline and 3 and/or 6 months of dutasteride treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate volume parameters</measure>
    <time_frame>Baseline and 3 and/or 6 months of dutasteride treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life parameters</measure>
    <time_frame>Baseline and 3 and/or 6 months of dutasteride treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LUTS Symptom parameters</measure>
    <time_frame>Baseline and 3 and/or 6 months of dutasteride treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LUTS outcome score</measure>
    <time_frame>Baseline and 3 and/or 6 months of dutasteride treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient perceptions</measure>
    <time_frame>Baseline and 3 and/or 6 months of dutasteride treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters</measure>
    <time_frame>Baseline and 3 and/or 6 months of dutasteride treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Dutasteride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dutasteride</intervention_name>
    <description>Dutasteride 0.5 mg od.</description>
    <arm_group_label>Dutasteride</arm_group_label>
    <other_name>Avodart</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age≥50 and &lt;80 years old&#xD;
&#xD;
          2. Presence of LUTS for at least 3 months&#xD;
&#xD;
          3. IPSS≥15&#xD;
&#xD;
          4. Bladder outlet obstruction confirmed by pressure-flow study (BOOI &gt; 20)&#xD;
&#xD;
          5. Prostate volume measured by TRUS ≥ 30ml and &lt; 100ml&#xD;
&#xD;
          6. Able to comply with the prescribed treatment protocol and evaluations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with neurogenic voiding disorders&#xD;
&#xD;
          2. Patients with prostate or bladder cancer&#xD;
&#xD;
          3. Patients underwent urethral, prostate or bladder neck surgery&#xD;
&#xD;
          4. Patients with urethral stricture or bladder neck contracture&#xD;
&#xD;
          5. Serum PSA≥4ng/ml (if the patient confirmed as no malignancy by prostate biopsy can be&#xD;
             included).&#xD;
&#xD;
          6. Patients who medicated with 5ARI within 6 months&#xD;
&#xD;
          7. Patients who do not agree with the informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyu-Sung Lee, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>January 22, 2009</study_first_submitted>
  <study_first_submitted_qc>January 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2009</study_first_posted>
  <last_update_submitted>June 8, 2009</last_update_submitted>
  <last_update_submitted_qc>June 8, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2009</last_update_posted>
  <responsible_party>
    <name_title>Kyu-Sung Lee/Professor</name_title>
    <organization>Samsung Medical Center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dutasteride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

